View Post

Debunking 4 myths about cancer clinical trials: The unsung hero of breast cancer research

In In The News by Barbara Jacoby

By: Anil Sethi From: medcitynews.com Clinical trials are the safest and most trusted route for identifying new breast cancer treatments, and the more research that can be done, the closer we will be to eradicating breast cancer for good. Clinical trials are the most effective tool to finding groundbreaking medical treatments. The first large-scale breast cancer prevention study in 1998, …

View Post

New drug class could treat range of cancers with faulty BRCA genes

In Clinical Studies News by Barbara Jacoby

By: Institute of Cancer Research From: medicalxpress.com Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumors have faulty copies of the BRCA cancer genes. The drugs, known as POLQ inhibitors, specifically kill cancer cells with mutations in the BRCA genes while leaving healthy cells unharmed. And crucially, they can kill …

View Post

Is Breast Cancer Curable? Get the Facts

In In The News by Barbara Jacoby

From: healthline.com There’s currently no cure for metastatic breast cancer, but new treatments have improved survival rates in recent years. Researchers have gained a better understanding of the molecular and genetic characteristics of breast cancer. Improved understanding of breast cancer may help experts develop more personalized treatment plans for people with this condition. Experts now know that breast cancer isn’t …

View Post

Sanofi’s, AstraZeneca’s and Radius’ oral SERDs could establish clinical worth in ER+ breast cancer by showing similar efficacy to Faslodex, experts say

In Clinical Studies News by Barbara Jacoby

By: Manasi Vaidyacl From: clinicaltrialsarena.com Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, AstraZeneca’s Faslodex (fulvestrant) or generic aromatase inhibitors in oestrogen receptor positive (ER+) HER2-negative breast cancer, said experts. Oral SERDs by AstraZeneca, Sanofi and Radius Health can demonstrate clinical value by being comparable, rather than superior to, …

View Post

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease. The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast …

View Post

Trial Explores Preoperative Window for Amcenestrant Therapy in Early Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Denise Myshko From: onclive.com Investigators are seeking to determine whether amcenestrant (SAR439859), an investigational oral endocrine therapy, can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer. The phase 2 AMEERA-4 trial (NCT04191382) is testing 2 dose levels of amcenestrant versus letrozole given for 14 days to patients with …

View Post

FDA Grants Premarket Approval to Diagnostic Breast Cancer Imaging Technology

In Clinical Studies News by Barbara Jacoby

By: Kristi Rosa From: onclive.com The FDA’s Center for Devices and Radiological Health has granted premarket approval (PMA) to diagnostic breast cancer imaging technology developed by Seno Medical Instruments to assist in the differentiation between benign and malignant breast lesions in patients.1 By using noninvasive poto-acoustic ultrasound technology, the Imagio Breast Imaging System is able to produce data on suspicious …

View Post

Uptake of Breast Cancer Clinical Trials at Minority Serving Cancer Centers

In Clinical Studies News by Barbara Jacoby

By: DocWire News Featured Reading From: docwirenews.com ABSTRACT BACKGROUND: Most minorities receive cancer care at minority-serving hospitals (MSHs) that have been associated with disparate treatment between Black and White patients. OBJECTIVE: Our aim was to examine the uptake of clinical trials that have changed axillary management in breast cancer patients at MSH and non-MSH cancer centers. METHODS: The National Cancer …

View Post

Practicing Outside the Pharma Box in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Dawn Fallik From: onclive.com When Martine Piccart, MD, PhD, was a child, she sometimes watched her father, a gynecologist, talk to his patients. She remembers his respect for them and their families and the way he communicated, focusing on the positive but not shying away from delivering bad news. “He always took the time to explain in detail not …